78712-43-3

Basic information

• Product Name: Ozagrel hydrochloride
• Synonyms: (e)-3-(4-(1h-imidazol-1-ylmethyl)phenyl)-2-propenoicacidhydrochloridehydra;(e)-ohydrat;2-propenoicacid,3-(4-(1h-imidazol-1-ylmethyl)phenyl)-,monohydrochloride,mon;oky046hydrochloride;oky-046hydrochloride;OZAGREL HYDROCHLORIDE HYDRATE;OzagrelHcl99%;OzagrelHclC13H12N2O2.Hcl
• CAS NO: 78712-43-3
• Molecular Formula: C₁₃H₁₂N₂O₂*ClH
• Molecular Weight: 264.71
• EINECS: 1312995-182-4
• Product Categories: Cardiovascular;Inhibitors;Piperidones ,Piperidines ,Homopiperidines
• Mol File: 78712-43-3.mol
• Article Data: 3

Chemical Properties

• Melting Point: 214-217°
• Boiling Point: 468 °C at 760 mmHg
• Flash Point: 236.8 °C
• Appearance: white to off-white/solid
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: H2O: soluble
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in distilled water may be stored at -20° for up to 1 month.
• Merck: 14,6980
• CAS DataBase Reference: Ozagrel hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Ozagrel hydrochloride(78712-43-3)
• EPA Substance Registry System: Ozagrel hydrochloride(78712-43-3)

Safety Data

• RIDADR: 3077
• WGK Germany: 2
• RTECS: UD3380000
• Hazardous Substances Data: 78712-43-3(Hazardous Substances Data)

Usage

Description

Ozagrel HCl (78712-43-3) is a potent and selective inhibitor of thromboxane (TXA2) synthetase (IC50 = 4 nM).1?Does not inhibit prostacyclin (PGI2) synthase, cyclooxygenase or PGE2?isomerase (IC50 > 1 mM).1?Inhibits platelet aggregation2?in vitro?and arachidonate-induced arterial contraction?in vivo. Ozagrel HCl protects against arachidonate-induced sudden death in the rabbit3, and alleviates liver injury induced by acetaminophen overdose in mice4.

Uses

Antithrombotic;Thromboxane synthase inhibitor

References

1) Hiraku?et al. (1986),?Pharmacological studies on the TXA2?synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046); Jpn. J. Pharmacol.,?41?393 2) Naito?et al. (1983), Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets; Eur. J. Pharmacol.,?91?41 3) Edmonds and Leffer (1984),?Protective actions of a new thromboxane synthetase inhibitor in arachidonate induced sudden death; Life Sci.,?35?1763 4) Tomishima?et al. (2013),?Ozagrel hydrochloride, a selective thromboxane A2?synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice; BMC Gastroenterol.,?30?13

InChI:InChI=1/C12H12N2O.ClH/c15-8-5-11-1-3-12(4-2-11)9-14-7-6-13-10-14;/h1-8,10,15H,9H2;1H/b8-5+;

Upstream product

• 73291-09-5 4-chloromethylbenzaldehyde 
• 18282-51-4 4-iodo-benzyl alcohol 
• 1575769-60-6 ozagrel butyl ester 
• 1145685-38-6 (E)-4-(hydroxymethyl)cinnamic acid butyl ester 
• 141-82-2 malonic acid 
• 102432-03-1 4-((1H-imidazol-1-yl)methyl)benzaldehyde 

Downstream Products

• 82571-53-7 ozagrel 

Relevant articles and documents

Photoisomerization of Sulindac and Ozagrel Hydrochloride by Vitamin B2 Catalyst Under Visible Light Irradiation

Purpose: Photoisomerization of the E/Z-alkene structures of drugs is a matter of concern as it could result in potency loss and adverse side effects. This study focused on light-induced isomerization of sulindac and ozagrel hydrochloride catalyzed by concomitant vitamin B2 under light-emitting diode (LED) or fluorescent light. Methods: In the presence of 0.05/0.03 equivalents of vitamin B2/flavin adenine dinucleotide (FAD), sulindac or ozagrel hydrochloride was irradiated with LED light (405?nm) or fluorescent light. The photoisomerization in CD3OD and D2O was monitored by 1H NMR spectroscopy. Results: Sulindac and ozagrel hydrochloride isomerized in the presence of a catalytic amount of vitamin B2 or FAD under irradiation of 405?nm LED light and fluorescent light. Irradiation with LED light was found to be more effective than fluorescent light irradiation. The rate of photoisomerization was affected by the solvent, and the reaction in CD3OD proceeded faster than in D2O. Furthermore, ozagrel hydrochloride was more prone to isomerization than sulindac. Conclusion: The catalytic activity of vitamin B2 or FAD was demonstrated in the photoisomerization reaction of sulindac and ozagrel hydrochloride. Considering that the rate of photoisomerization in D2O is very slow, the possibility of the occurrence of photoisomerization during clinical use is low. However, this study suggests that the interfusion of vitamin B2 or FAD under excessive light exposure should be avoided as a caution during intravenous administration of sulindac or ozagrel hydrochloride.

A new route for the synthesis of ozagrel hydrochloride

-